Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study

Psychiatry Research - Neuroimaging

Volumn 221, Issue 3, 2014, Pages 231-239

  Conway, Charles R ^a,b   Chibnall, John T ^b   Cumming, Paul ^c   Mintun, Mark A ^a,d   Gebara, Marie Anne I ^a   Perantie, Dana C ^a   Price, Joseph L ^a   Cornell, Martha E ^a   McConathy, Jonathan E ^a   Gangwani, Sunil ^a   Sheline, Yvette I ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Aripiprazole; Caudate; Dopamine; Positron emission tomography; Treatment resistant depression

Indexed keywords

ARIPIPRAZOLE; CAUDATE; DOPAMINE; POSITRON EMISSION TOMOGRAPHY; TREATMENT-RESISTANT DEPRESSION;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; CAUDATE NUCLEUS; CITALOPRAM; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGONISTS; DRUG SYNERGISM; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; QUINOLONES; SAMPLE SIZE; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84894317267     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2014.01.003     Document Type: Article

References (67)

1. Aihara K., Shimada J., Miwa T., Tottori K., Burris K.D., Yocca F.D., Horie M., Kikuchi T. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Research 2004, 1003(1-2):9-17.
2. American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC, American Psychiatric Publishing (Text revision).
3. Barnes T.R. A rating scale for drug-induced akathisia. The Britsh Journal of Psychiatry 1989, 154:672-676.
4. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQuade R.D., Carson W.H., Adson D., Taylor L., Hazel J., Marcus R.N. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009, 14:197-206.
5. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2007, 68:843-853.
6. Brunswick D.J., Amsterdam J.D., Mozley P.D., Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. The American Journal of Psychiatry 2003, 160:1836-1841.
7. Buchsbaum M.S., Wu J., DeLisi L.E., Holcomb H., Kessler R., Johnson J., King A.C., Hazlett E., Langston K., Post R.M. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. Journal of Affective Disorders 1986, 10:137-152.
8. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 2002, 302:381-389.
9. Busto U.E., Redden L., Mayberg H., Kapur S., Houle S., Zawertailo L.A. Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse 2009, 63:681-689.
10. Cho S., Neff N.H., Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic l-amino acid decarboxylase by dopaminergic drugs. European Journal of Pharmacology 1997, 323:149-157.
11. Cumming P., Ase A., Laliberte C., Kuwabara H., Gjedde A. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. Journal of Cerebral Blood Flow and Metabolism 1997, 17:1254-1260.
12. Cumming P., Kuwabara H., Ase A., Gjedde A. Regulation of DOPA decarboxylase activity in brain of living rat. Journal of Neurochemistry 1995, 65:1381-1390.
13. Danielsen E.H., Smith D., Hermansen F., Gjedde A., Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 2001, 41:172-175.
14. Demyttenaere K., De Fruyt J., Stahl S.M. The many faces of fatigue in major depressive disorder. The International Journal of Neuropsychopharmacology 2005, 8:93-105.
15. Dhawan V., Ma Y.L., Pillai V., Spetsieris P., Chaly T., Belakhlef A., Margouleff C., Eidelberg D. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. Journal of Nuclear Medicine 2002, 43:1324-1330.
16. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Archives of General Psychiatry 2007, 64:327-337.
17. Ebert D., Feistel H., Kaschka W., Barocka A., Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation-preliminary results. Biological Psychiatry 1994, 35:880-885.
18. Echternacht R. Neuropsychological assessment of motor functioning - the Finger Tapping Test - data on an adult, female, inpatient psychiatric population. International Journal of Clinical Neuropsychology 1981, 3:8-9.
19. Eisenstein S.A., Koller J.M., Piccirillo M., Kim A., Antenor-Dorsey J.A.V., Videen T.O., Snyder A.Z., Karimi M., Moerlein S.M., Black K.J., Perlmutter J.S., Hershey T. Characterization of extrastriatal D2 in vivo specific binding of [18F](N-methyl)benperidol using PET. Synapse 2012, 66:770-780.
20. Ersche K.D., Cumming P., Craig K.J., Muller U., Fineberg N.A., Bullmore E.T., Robbins T.W. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?. Journal of Psychopharmacology 2012, 26:887-890.
21. Ferry A.T., Ongur D., An X., Price J.L. Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. Journal of Comparative Neurology 2000, 425:447-470.
22. Gershon A.A., Vishne T., Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biological Psychiatry 2007, 61:145-153.
23. Grunder G., Carlsson A., Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of General Psychiatry 2003, 60(10):974-977.
24. Guy, W., National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., Early Clinical Drug Evaluation Program., 1976. ECDEU assessment manual for psychopharmacology, Rev. ed. U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
25. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967, 6:278-296.
26. Hoshi H., Kuwabara H., Leger G., Cumming P., Guttman M., Gjedde A. 6-[18F]fluoro-l-dopa metabolism in living human brain: a comparison of six analytical methods. Journal of Cerebral Blood Flow and Metabolism 1993, 13:57-69.
27. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. Journal of Pharmacology and Experimental Therapeutics 1996, 277(1):137-143.
28. Inoue A., Miki S., Seto M., Kikuchi T., Morita S., Ueda H., Misu Y., Nakata Y. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology 1997, 321(1):105-111.
29. Ito H., Takano H., Arakawa R., Takahashi H., Kodaka F., Takahata K., Nogami T., Suzuki M., Suhara T. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with l-[beta-11C]DOPA. PLoS One 2012, 7(9):e46488.
30. Jokinen P., Helenius H., Rauhala E., Bruck A., Eskola O., Rinne J.O. Simple ratio analysis of F-18-fluorodopa uptake in striatal subregions separates patients with early parkinson disease from healthy controls. Journal of Nuclear Medicine 2009, 50:893-899.
31. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 2002, 441:137-140.
32. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. The American Journal of Psychiatry 1996, 153:466-476.
33. Keedwell P.A., Andrew C., Williams S.C.R., Brammer M.J., Phillips M.L. The neural correlates of anhedonia in major depressive disorder. Biological Psychiatry 2005, 58:843-853.
34. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction 1997, Lippincott-Raven, Philadelphia.
35. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinon e (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics 1995, 274(1):329-336.
36. Klimek V., Maj J. Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2-receptors. Journal of Pharmacy and Pharmacology 1989, 41:555-558.
37. Krishnan K.R., McDonald W.M., Escalona P.R., Doraiswamy P.M., Na C., Husain M.M., Figiel G.S., Boyko O.B., Ellinwood E.H., Nemeroff C.B. Magnetic resonance imaging of the caudate nuclei in depression. Preliminary observations. Archives of General Psychiatry 1992, 49:553-557.
38. Kumakura Y., Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 2009, 15:635-650.
39. Kumakura Y., Vernaleken I., Buchholz H.G., Borghammer P., Danielsen E., Grunder G., Heinz A., Bartenstein P., Cumming P. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiology of Aging 2010, 31:447-463.
40. Lahti R.A., Figur L.M., Piercey M.F., Ruppel P.L., Evans D.L. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Molecular Pharmacology 1992, 42(3):432-438.
41. Lancaster J.L., Glass T.G., Lankipalli B.R., Downs H., Mayberg H., Fox P.T. A modality-independent approach to spatial normalization of tomographic images of the human brain. Human Brain Mapping 1995, 3:209-223.
42. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612-627.
43. Maj J., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z. Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. European Journal of Pharmacology 1998, 351:31-37.
44. Maj J., Papp M., Skuza G., Bigajska K., Zazula M. The influence of repeated treatment with imipramine, (+)- and (-)-oxaprotiline on behavioural effects of dopamine D-1 and D-2 agonists. Journal of Neural Transmission 1989, 76:29-38.
45. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2008, 28:156-165.
46. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., Martinot J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. The American Journal of Psychiatry 2001, 158:314-316.
47. Matsubara K., Watabe H., Kumakura Y., Hayashi T., Endres C.J., Minato K., Iida H. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for [F-18]FDOPA PET by a model with detailed dopamine pathway. Synapse 2011, 65:751-762.
48. Meller E., Bohmaker K., Goldstein M., Basham D.A. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine-D(3) receptors. European Journal of Pharmacology 1993, 249:R5-R6.
49. Mizrahi R., Mamo D., Rusjan P., Graff A., Houle S., Kapur S. The relationship between subjective well-being and dopamine D-2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. International Journal of Neuropsychopharmacology 2009, 12(5):715-721.
50. Momiyama T., Amano T., Todo N., Sasa M. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. European Journal of Pharmacology 1996, 310(1):1-8.
51. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. The Britsh Journal of Psychiatry 1979, 134:382-389.
52. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006, 59:1151-1159.
53. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry 2001, 50:345-350.
54. Pae C.U., Serretti A., Patkar A.A., Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008, 22:367-388.
55. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
56. Savitz J., Lucki I., Drevets W.C. 5-HT1A receptor function in major depressive disorder. Progress in Neurobiology 2009, 88:17-31.
57. Schneier F.R., Liebowitz M.R., Abi-Dargham A., Zea-Ponce Y., Lin S.H., Laruelle M. Low dopamine D-2 receptor binding potential in social phobia. The American Journal of Psychiatry 2000, 157:457-459.
58. Semba J., Watanabe A., Kito S., Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995, 34(7):785-791.
59. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychological Medicine 1997, 27:1247-1256.
60. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(20):22-33. (quiz 34-57).
61. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum 1970, 212:11-19.
62. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology 2005, 515(1-3):10-19.
63. Takahata K., Ito H., Takano H., Arakawa R., Fujiwara H., Kimura Y., Kodaka F., Sasaki T., Nogami T., Suzuki M., Nagashima T., Shimada H., Kato M., Mimura M., Suhara T. Striatal and extrastriatal dopamine D(2) receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [(1)(1)C]raclopride and [(1)(1)C]FLB457. Psychopharmacology (Berlin) 2012, 222(1):165-172.
64. Talairach J., Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. 1988, Thieme Medical Publishers, Stuttgart, New York. G. Thieme (Ed.).
65. Vernaleken I., Kumakura Y., Cumming P., Buchholz H.G., Siessmeier T., Stoeter P., Muller M.J., Bartenstein P., Grunder G. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 2006, 30:1332-1339.
66. Yokoi F., Grunder G., Biziere K., Stephane M., Dogan A.S., Dannals R.F., Ravert H., Suri A., Bramer S., Wong D.F. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002, 27(2):248-259.
67. Zhu M.Y., Juorio A.V., Paterson I.A., Boulton A.A. Regulation of striatal aromatic l-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. European Journal of Pharmacology 1993, 238:157-164.